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INTRODUCTION
There is increasing evidence that inadequate sleep (for re-
views, see 1,2) and specific sleep disorders such as OSA (for 
A workshop was held at the National Institute for Diabetes and Digestive and Kidney Diseases with a focus on the impact of sleep and circadian 
disruption on energy balance and diabetes. The workshop identified a number of key principles for research in this area and a number of specific 
opportunities. Studies in this area would be facilitated by active collaboration between investigators in sleep/circadian research and investigators 
in metabolism/diabetes. There is a need to translate the elegant findings from basic research into improving the metabolic health of the American 
public. There is also a need for investigators studying the impact of sleep/circadian disruption in humans to move beyond measurements of 
insulin and glucose and conduct more in-depth phenotyping. There is also a need for the assessments of sleep and circadian rhythms as well as 
assessments for sleep-disordered breathing to be incorporated into all ongoing cohort studies related to diabetes risk. Studies in humans need 
to complement the elegant short-term laboratory-based human studies of simulated short sleep and shift work etc. with studies in subjects in the 
general population with these disorders. It is conceivable that chronic adaptations occur, and if so, the mechanisms by which they occur needs 
to be identified and understood. Particular areas of opportunity that are ready for translation are studies to address whether CPAP treatment of 
patients with pre-diabetes and obstructive sleep apnea (OSA) prevents or delays the onset of diabetes and whether temporal restricted feeding 
has the same impact on obesity rates in humans as it does in mice.
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reviews, see 3,4) are independent risk factors for metabolic ab-
normalities such as insulin resistance and hyperglycemia. The 
sleep research community has also advanced our knowledge 
of possible mechanisms for the effects of inadequate sleep, ob-
structive sleep apnea, and other sleep disorders on metabolic 
function. In parallel to these advances, there has been substan-
tial progress in studies of the role of central and peripheral 
clocks in metabolic control and regulation of metabolism in 
basic and clinical science.
Thus, it seemed timely to bring together experts in metabo-
lism with experts in sleep and circadian research to assess our 
current knowledge and identify new opportunities for research. 
To accomplish this goal, the National Institute of Diabetes and 
Digestive and Kidney Diseases held a two-day workshop on 
A commentary on this article appears in this issue on page 1847.
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“Impact of Sleep and Circadian Disruption on Energy Balance 
and Diabetes.” The workshop was held at NIH in Bethesda on 
February 19–20, 2015. Invited participants gave presentations 
on their area of expertise. These presentations are summarized 
in this manuscript. This manuscript is not intended as a com-
prehensive review but rather a summary of the proceedings at 
the workshop. In addition, the Sleep Research Society orga-
nized a competitive process for travel awards for early-stage 
investigators to attend the workshop. The early-stage investi-
gators participated in discussions, presented posters and did 
the initial draft of this white paper. These individuals represent 
the future for investigation in this area and it is critical that 
they are involved in identification of gaps and obstacles in this 
scientific area.
A particular goal of the workshop was to identify opportu-
nities for translational research. Each invited participant dis-
cussed and presented their views on opportunities and needs 
for scientific development. These have been coalesced and are 
presented at the end of this document. 
SESSION I: SLEEP DISRUPTION AND SLEEP DISORDERS: 
EFFECTS ON METABOLIC DISEASE
Dr. Eve Van Cauter began the workshop with an overview of 
the literature surrounding the associations between sleep dis-
turbances, circadian dysfunction and diabetes risk, which has 
garnered both public and scientific interest. In a seminal study, 
by Spiegel and colleagues,5 the effect of short sleep on diabetes 
risk was examined utilizing an intravenous glucose tolerance 
test following either 5 nights of chronic partial sleep loss (4 
h/night) or 5 nights in the rested condition (12 h/night). Remark-
ably, insulin sensitivity as well as disposition index, a marker 
of diabetes risk, were significantly decreased in the sleep loss 
condition. Impaired glucose metabolism has been observed in 
subsequent experimental studies with varying degrees of sleep 
loss.2,6–10 A recent paper revealed that sleep restriction has an 
impact on the molecular mechanisms in peripheral tissues, 
specifically adipocytes.8 In a randomized crossover design, 
subcutaneous fat biopsy samples were collected from 7 healthy 
lean participants following either 4 days of 4.5 h/night or 8 
h/night of sleep in the laboratory. The isolated adipocytes were 
treated with increasing concentrations of insulin and measured 
for levels of phosphorylated Akt (pAkt), a crucial step in the 
insulin-signaling pathway. Following 4 nights of sleep defi-
ciency, adipocytes exhibited a 30% reduction in insulin sen-
sitivity as compared to those collected following 4 nights of 
normal sleep.8 Thus, to elicit the same pAkt response observed 
following normal sleep, higher concentrations of insulin were 
necessary in adipocytes following 4 nights of restricted sleep. 
The 30% reduction in insulin sensitivity observed in this study 
is similar to that seen in individuals with diabetes compared to 
controls11 and in obese individuals when compared to lean in-
dividuals.12 The direct action of sleep deficiency on peripheral 
adipose tissue may affect energy metabolism via alterations to 
insulin sensitivity within adipocytes.
Multiple studies have also recently been initiated to explore 
whether sleep extension and/or improvement in sleep quality 
will benefit glucose tolerance. Individuals who curtailed bed-
times on a regular basis were studied under habitual sleep con-
ditions and following 6 weeks of sleep extension. On average, 
the participants extended sleep time by approximately 45 min 
during weekdays with no change on the weekends.9 As sleep 
time increased, particularly the amount of stage N2, the Ho-
meostatic Model Assessment (HOMA) values (a marker of 
insulin resistance) decreased, while the Quantitative Insulin 
Sensitivity Check Index (QUICKI),13 a marker of insulin sensi-
tivity, increased. Taken together, the current body of evidence 
indicates that sleep restriction has a detrimental effect on in-
sulin sensitivity while sleep extension in restricted sleepers 
may actually improve glucose tolerance.
Circadian disturbance may also affect glucose metabolism. 
Low nocturnal melatonin secretion has been associated with 
increased diabetes risk and variants in the melatonin receptor 
that result in reduced function are associated with elevated 
glucose levels and increased risk of diabetes.14–16 In a study of 
370 women, low melatonin secretion was independently asso-
ciated with a higher risk of developing type 2 diabetes.17 When 
the circadian system is misaligned, desynchrony between the 
central and peripheral clocks occurs and glucose metabolism 
is adversely affected.18 Under a forced desynchrony protocol, 
when subjects slept and ate approximately 12 h out of phase 
relative to their endogenous circadian time conditions, an ex-
aggerated postprandial glucose response was observed, which 
resulted in an overall increase in glucose levels.19 Most inter-
estingly, glucose levels were elevated despite a concurrent rise 
in insulin levels, suggesting a decrease in insulin sensitivity 
resulting from circadian misalignment. In a recent laboratory 
study, when sleep restriction and circadian misalignment were 
combined, the reduction in insulin sensitivity in the male par-
ticipants was almost twofold higher than that observed with 
nocturnal sleep restriction alone.20 Lastly, it has been reported 
that chronotype is associated with altered glycemic control 
in patients with type 2 diabetes.21 Those with a later chrono-
type, associated with a greater degree of circadian misalign-
ment, had higher HbA1C levels after controlling for multiple 
confounders. Taken together, these data suggest that circadian 
misalignment adversely affects glucose metabolism, and fur-
thermore that combining circadian misalignment with sleep 
restriction, a common occurrence during shift work, can exag-
gerate this effect.
In summary, there is a body of experimental evidence in 
support of a causal relationship between sleep and circadian 
disturbances and increased metabolic risk. Proof of concept 
studies examining whether optimizing sleep and/or circadian 
function can reduce the risk or severity of diabetes have only 
been recently initiated by a number of independent inves-
tigators. The next few years will see the findings from these 
efforts. Molecular mechanisms linking insufficient sleep, cir-
cadian dysfunction and metabolism remain largely unexplored. 
Of note, studies using animal models to examine metabolic 
consequences of circadian disruption rarely control for sleep 
duration or quality. Conversely, the vast majority of clinical 
diabetes research ignores sleep duration, sleep quality, pres-
ence of OSA and circadian phenotype as confounding predic-
tors of diabetes risk and severity. Clinical trials for diabetes 
prevention or treatment should include assessment of habitual 
sleep duration and quality as well as exposure to circadian 
disruptors such as light at night, shift work and social jet lag. 
Individual differences in response to sleep restriction or/and 
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sleep extension need to be explored. The feasibility and mo-
dalities for optimizing sleep and circadian function as novel 
behavioral interventions to prevent or treat diabetes are areas 
of opportunity.
OBSTRUCTIVE SLEEP APNEA AND DIABETES: CLINICAL 
STUDIES AND MECHANISMS
Dr. Allan Pack provided an overview of the data linking 
OSA and diabetes from both clinical and mechanistic perspec-
tives. Obesity is a major risk factor that plays an important role 
in many proposed pathways. OSA is increasingly prevalent, as 
indicated by a recent report from the Wisconsin Sleep Cohort 
that estimated the current prevalence among those age 50–70 
to be 17.4% in men and 9.1% in women, compared to previous 
data that suggested rates of 13.9% in men and 7.4% in women.22
Those with moderate to severe OSA have much higher levels 
of insulin resistance, even after controlling for the degree of 
adiposity.23,24 A recent meta-analysis showed that CPAP treat-
ment improves insulin resistance in patients with sleep apnea 
without diabetes.25 This is consonant with a meta-analysis by 
Yang and colleagues that showed similar results in observa-
tional studies.26 Botros and colleagues showed that those with 
OSA are more likely to develop diabetes.27 This report was 
included in a subsequent meta-analysis that showed that OSA 
is associated with an overall odds ratio of 1.6 for incident dia-
betes. Further, use of CPAP may reduce the observed diabetes 
risk.27 This is in the context of studies that show that there is a 
very high prevalence of OSA in patients with type 2 diabetes28 
and that OSA severity is associated with increasing HbA1c.29
OSA leads to both chronic intermittent hypoxia and distur-
bances in sleep continuity (sleep fragmentation and arousals). 
These, in turn, are associated with oxidative stress (and reac-
tive oxygen species), increased activity in the nuclear factor κB 
(NF-κB) pathway, and sympathetic activation. These physio-
logic changes can interact and lead to a number of downstream 
changes, including HIF-1α activation,30 elevated adhesion 
molecules,31 elevated adipokines,32 and increased free fatty 
acids.33 Cyclical intermittent hypoxia (CIH), akin to that oc-
curring in sleep apnea, can be simulated in animal models.34 
This has been used to demonstrate that CIH impairs glucose 
homeostasis.35 Prabhakar and colleagues36 have described mo-
lecular pathways by which chronic intermittent hypoxia leads 
to increases in HIF-1α and pro-oxidants as well as decreases 
in HIF-2α and antioxidants by a calpase enzyme mechanism. 
The resulting activation of the carotid body results in increased 
catecholamines due to adrenal medullary and sympathetic 
neuronal activation. This is supported by data from Shin and 
colleagues, who showed that the effects of intermittent hy-
poxia on glucose tolerance are blocked by carotid sinus nerve 
sectioning.37 There are also data suggesting a link between cy-
clical intermittent hypoxia and β-cell function.38 An important 
caveat is that these studies largely use extreme hypoxia that 
is not relevant for the vast majority of patients. The effects of 
cyclical intermittent hypoxia in mice on lipids are only seen at 
very severe levels of hypoxia.39 Thus, there is a need for studies 
with cyclical intermittent hypoxia that study the effects of less 
extreme levels of hypoxia that are relevant to clinical patients.
Intermediate pathways and other factors triggered by in-
termittent hypoxemia may contribute to insulin resistance, 
hypertension, and cardiovascular disease. Not only is obesity 
also associated with these same changes, but it is associated 
with sleep apnea as well. This represents a complex associa-
tion whereby the role of CPAP in cardiometabolic risk may be 
moderated by obesity and/or weight loss.40–43
In addition to intermittent hypoxia, sleep fragmentation may 
itself lead to diabetes risk. Sleep fragmentation can be induced 
in mice with minimal effects on total sleep duration. Sleep loss 
induces the unfolded protein response in brain.44 Wang and 
colleagues found increases in food intake and body weight in 
mice over 8 weeks of sleep fragmentation.45 Sleep disruption 
leads to increased endoplasmic reticulum stress in the hypo-
thalamus with an upregulation of expression of a number of 
molecular chaperones.46 There is also an increase in protein-
tyrosine phosphatase 1B (PTP1B), which can lead to attenua-
tion in leptin receptor signaling.46 As leptin is a key molecule 
in signaling pathways that control satiety,47,48 this could poten-
tially explain a connection between sleep fragmentation and 
food intake. NADPH oxidase 2 (NOX2) enzyme, which results 
in production of reactive oxygen species, may be another po-
tential pathway linking sleep fragmentation with diabetes.49 
Using NOX2 KO mice, Zhang and colleagues found that al-
terations in glucose tolerance, induced by sleep fragmentation, 
were mediated by NOX2.50
Dr. Naresh Punjabi continued the discussion about OSA and 
diabetes risk. He reviewed and cited studies that reported an as-
sociation between OSA and metabolic dysfunction. Following 
this, Dr. Punjabi discussed randomized controlled trials that 
have investigated the impact of CPAP treatment on metabolic 
outcomes in OSA patients. The majority of the reported studies 
are small, from clinic-based samples and vary with respect to 
the extent of CPAP adherence and the type of measures for 
assessing metabolic dysfunction (e.g., fasting glucose, HbA1c, 
oral glucose tolerance test). These methodological differences 
result in conflicting data on the efficacy of CPAP treatment 
for metabolic disorders in OSA patients. Dr. Punjabi also pre-
sented his data from animal models demonstrating that 7 days 
of intermittent hypoxia decreases glucose tolerance, β-cell 
function, and insulin sensitivity and increases pancreatic lipid 
peroxidation in mice.35 Exposing the mice subsequently to 7 
days of normoxia did not reverse the effects of intermittent 
hypoxia on glucose tolerance, β-cell dysfunction or pancreatic 
lipid peroxidation. These results suggest that intermittent hy-
poxia may cause irreversible metabolic effects, underscoring 
the potential importance of early intervention in OSA. Dr. Pun-
jabi concluded that much more research is needed to investi-
gate the role OSA in metabolic dysfunction. Specifically, large, 
multi-centered clinical trials are needed to investigate the im-
pact of OSA treatment on metabolic outcomes such as whether 
treatment of patients with OSA with CPAP therapy can induce 
clinically significant improvements in insulin sensitivity and 
glucose tolerance. A particular area of opportunity is to deter-
mine whether CPAP treatment in patients with OSA and pre-
diabetes can reduce the incident rate of diabetes. Observational 
data27 suggest that this is so but a randomized trial is required 
to assess this definitively. A recent laboratory-based study has 
shown improvement in glucose metabolism with CPAP in OSA 
patients with pre-diabetes.51 In the context of such studies, it is 
important to examine the possible effects of OSA severity and 
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other patient-related factors such as age on treatment-related 
improvements in metabolic function. Moreover, studies need 
to account for duration of metabolic dysfunction in the assess-
ment of whether CPAP has less favorable effects in those with 
longstanding disease.
SESSION II: NEURAL REGULATION OF ENERGY BALANCE, 
SLEEP, AND CIRCADIAN RHYTHMS
The talks in this section focused on several interrelated 
themes and approaches that could be applied to the challenges 
in this area of research. Dr. Joel Elmquist focused on hypotha-
lamic control of metabolism and feeding, particularly on the 
role of leptin and POMC neurons, and novel tools that can be 
used to probe these functions. Dr. Etienne Challet discussed 
the importance of incorporating diurnal species into the in-
vestigation of circadian effects on metabolic function, and 
also emphasized that many metabolic changes observed in 
circadian disruption are similar to those observed in aging. 
Finally, Dr. Paul Franken proposed the novel hypothesis that 
clock genes may be an important common pathway by which 
both circadian disruption and sleep disruption exert effects on 
metabolic processes.
The overall focus of Dr. Elmquist’s talk was on the role of 
leptin signaling in chemically identified neurons thereby pro-
viding increased resolution of the neural circuits that mediate 
feeding and satiety. He discussed tools that can be used to dis-
sect the hypothalamic feeding circuits that include neurons ex-
pressing neuropeptide-Y (NPY), agouti-related peptide (AgRP), 
and pro-opiomelanocortin (POMC).52 Dr. Elmquist presented 
the current prevalent model of energy balance by which AgRP 
stimulates food intake and alpha melanocyte stimulating 
hormone (α-MSH) decreases food intake by acting through 
second order neurons in the hypothalamus. He then explained 
how leptin can modulate this system by increasing the activity 
of α-MSH neurons and decreasing the activity of AgRP cells. 
Given the opposite effects of leptin (primarily produced by 
adipocytes) on food consumption through α-MSH and AgRP 
neurons, analysis of these circuits is difficult. Thus, Dr. El-
mquist described efforts to modulate the activity of the leptin 
receptor (LepR) in specific sub-types of neurons using Cre-lox 
approaches, and the insights that have followed.53,54 Coupling 
this approach with inducible CRE recombination activated by 
a tamoxifen-specific estrogen receptor further provides tem-
poral control. To emphasize the complexity of interactions at 
POMC neurons in the arcuate nucleus of the hypothalamus, Dr. 
Elmquist showed that serotonin (5-HT), acting through mul-
tiple receptors, can have differential effects on cells in the cir-
cuit, thus producing specific and separable responses.
Dr. Elmquist’s elegant work illustrated that signaling within 
the hypothalamic feeding circuit is nuanced, and sophisticated 
approaches using genetic targeting of chemically identified 
cells, as well as temporal control using conditional repres-
sion, can be leveraged to better understand the system. Even 
when the phenotype of the neurons involved is identified, fur-
ther complexity is caused by differential outcomes driven by 
specific receptor activations; in the case of arcuate POMC 
neurons, 5-HT signaling through one of many receptors can 
have different outcomes on both physiology and feeding be-
havior. Thus, both developing new tools to refine the targeting 
to specific neuron types, as well as targeting specific intracel-
lular signaling cascades is an important approach to more fully 
dissect the role of the hypothalamus in feeding and metabolic 
function.
Dr. Etienne Challet presented work on how diurnal and 
nocturnal species differ in their circadian organization and re-
sponses to metabolic challenges.55 Despite behavior being se-
questered to different times, diurnal and nocturnal mammals 
share a conserved core oscillator. Peak Period1 expression in 
the SCN and circulating melatonin concentration, for example, 
occur at the same time of day in both groups. Other outputs 
of the clock are out of phase between diurnal and nocturnal 
organisms, including adrenal glucocorticoid secretion, leptin 
concentration, and behavioral state. Utilizing this dichotomy 
in central-peripheral phase angle between diurnal and noc-
turnal animals may contribute to understanding entrainment 
mechanisms. This could be particularly important in the study 
of metabolism, because in both diurnal and nocturnal species, 
light cues, food cues, and sleep debt all converge on peripheral 
organs but with differential effects.
Dr. Challet’s work has focused on the inter-relationships 
among metabolic disturbances, circadian disruptions, and 
sleep debt. Dr. Challet’s group looked at the effect of normo-
caloric and hypocaloric ultradian feeding. Timed hypocaloric 
feeding shifts molecular circadian rhythms in the suprachias-
matic nucleus. In diurnal rodents, the effect is to phase delay the 
rhythm while in nocturnal animals it leads to the opposite—a 
phase advance.55 High fat diets disturb circadian rhythms, flat-
tening the day-night pattern of food intake and lengthening the 
free-running period in constant darkness.56,57 Phase shifting 
and re-entrainment are also attenuated, implicating an effect 
on the SCN. Sleep debt also affects circadian rhythms and 
metabolic function and can have opposite effects in diurnal 
versus nocturnal rodents. For example, sleep deprivation and 
caffeine reduce phase shifts in nocturnal rodents and increase 
phase shifts in diurnal rodents.58,59 These manipulations also 
impair glucose tolerance in nocturnal rodents. Given these op-
posite effects in diurnal and nocturnal rodents, it is critically 
important to determine whether metabolic effects of sleep dis-
turbances are the same or different between the two groups. Dr. 
Challet introduced the term “chronobesity” for the increased 
body weight and impaired insulin secretion commonly caused 
by circadian disruption.60,61
In closing, Dr. Challet addressed two important concepts: 
(1) diurnal and nocturnal animals share some features, but re-
sponses to diet and sleep differ. Diurnal animals are, there-
fore, important chronobiological tools with great translational 
potential62; and (2) impaired metabolism caused by circadian 
disruption may signal accelerated aging, and can be studied 
in diurnal species. For example, circadian-disrupted grass rats 
exhibit shorter telomeres and impaired glucose responses in-
termediate between the glucose tolerance found in young and 
old animals.63
Dr. Paul Franken stressed the independent and combinato-
rial contributions of the circadian clock and the sleep-wake 
cycle on physiological and genomic rhythms. This is an im-
portant complement to the investigation of these separate ef-
fects in humans under conditions of forced desynchrony (see 
Session V, below).
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Physiology and behavior that remains rhythmic in constant 
conditions are often ascribed to an effect of the SCN clock; 
but other contributing factors such as sleep have been less well 
investigated. Twenty years ago, however, Dr. Franken showed 
that > 80% of the variation in daily rhythms of body tempera-
ture in the rat can be attributed to the sleep/wake cycle.64 In 
his talk, he presented his current systems biology approach to 
these questions. To determine the extent to which sleep and 
wake affect the transcriptional regulation of circadian rhythms, 
the transcriptome was examined in mice that were sleep de-
prived for 6 hours prior to sacrifice. Of ~2,000 genes that cycle 
in whole brain, only ~400 remained rhythmic in sleep deprived 
mice.65 Similar effects of sleep disruption have now been re-
ported in human blood as well.66,67 This is not surprising given 
that the sleep/wake cycle affects temperature, metabolism, in-
flammatory function, redox state, stress, and even light expo-
sure, all of which can directly alter gene expression.
Genes can therefore be classified as being regulated by 
the circadian cycle only (Bmal1), the sleep-wake cycle only 
(Homer1a)65, or by both (Per2).64,68 Per2 is of particular in-
terest as a core clock gene that is also sensitive to sleep. In vivo 
imaging of Per2 using the Per2::Luciferase knockin mouse69 
shows that sleep deprivation increases Per2 expression. The 
duration of the sleep deprivation effect depends on tissue; in 
liver, Per2 expression remains significantly elevated 6 hours 
after the intervention, even after expression has normalized 
in brain and kidney.70 Ultimately, the effects of sleep on gene 
expression rhythms depend on the gene, its location, and the 
time of the day.68,70–74
The change in expression across much of the genome may 
indicate that sleep alters the chromatin landscape. Bmal1 
binding to E box elements varies with time of day in many 
tissues, and 6 hours of sleep deprivation is sufficient to reduce 
BMAL1 binding to the promoter regions of Per2 as well as 
other genes.74 This is an important observation, since Bmal1 
has thousands of binding sites within the genome.75
Sleep is controlled by both a circadian process and a ho-
meostatic process 76 Given that sleep and waking have effects 
on core clock genes as part of their system-wide genetic ef-
fects, it may be that clock genes represent a common pathway 
by which both sleep disruptions and circadian disruptions are 
linked to their effects on energy metabolism.
SESSION III: MECHANISMS OF SLEEP AND CIRCADIAN 
DISRUPTION ON METABOLISM
Understanding how disrupting sleep and circadian behavior 
regulates metabolic function will require elucidating the mo-
lecular intersections between metabolic pathways and sleep 
and molecular clocks. In this section, three speakers described 
studies utilizing animal models to investigate the molecular 
links between the circadian clock and nutritional state. These 
studies highlight the utility of animal models ranging from 
fruit flies to rodents in discovery-oriented science, and the im-
portance of tissue specific analysis to dissect the relationship 
between circadian pacemaker neurons and metabolic function.
While it has long been known that circadian clocks in the 
brain drive feeding rhythms and these in turn impact liver 
clocks, much less is understood about how the clock regulates 
the physiology of other peripheral tissues. Work from Dr. Joe 
Bass reveals that global disruption of the circadian system 
through a mutation in the canonical circadian transcription 
factor, CLOCK, display a loss of rhythmic feeding and a host 
of diabetes and obesity-related disorders, including increased 
visceral adiposity and reduced glucose tolerance in mice.77 To 
explore the peripheral effects of circadian rhythms in pancre-
atic β-cells, Dr. Bass’ group performed adult-specific ablation 
of BMAL1, in β-cells in mice that results in hyperglycemia and 
hypoinsulinemia induced by reduced insulin exocytosis from 
β-cells.78 Thus, cell autonomous core clock function in β-cells 
affects insulin secretion from pancreatic β-cells. Loss of the 
clock in these cells results in hyperglycemia, phenocopying 
the increased glucose load observed in clinical studies. These 
findings provide strong evidence for tissue-specific function 
of local tissue clocks and highlight the utility of experimental 
genetic models for both in vivo and in vitro manipulation to 
dissect mechanistic actions of the clock within distinct cellular 
populations.
A number of studies indicate beneficial effects on life span 
and metabolism when feeding time is restricted to an animal’s 
active period. One explanation is that restricted feeding time 
is capable of aligning food intake with circadian expression 
of the appropriate genes in central and peripheral tissues.79 
Dr. Satchin Panda presented work examining the role of 
time-restricted feeding (TRF) on metabolic factors and gene 
expression profiles. Mice with food availability restricted to 
8 h/day during their waking period exhibited an increase in 
the number of cycling transcripts as well as a larger ampli-
tude in the diurnal rhythm of gene expression rhythms com-
pared to that in ad libitum fed animals, indicating this feeding 
regimen increases the robustness of peripheral circadian 
clocks.80 Placing animals on a TRF regimen does not impact 
overall food intake, but improves a number of traits associated 
with metabolic pathology including reduction in body weight, 
serum cholesterol, hepatic triglyceride levels, and insulin level 
fluctuations in microflora that are protective against the de-
velopment of obesity.81,82 Cardiac disease represents another 
common risk associated with sleep loss, circadian disruption 
and obesity. The effects of TRF on cardiac function are cur-
rently being studied in the fruit fly, Drosophila melanogaster. 
Flies provide a powerful system for genetic analysis of cardiac 
function, and flies display both age- and diet-dependent reduc-
tion in cardiac performance.83–85 The age-dependent reduction 
in cardiac performance is partially alleviated by TRF, and this 
improved function appears to be linked to TRF-dependent 
changes in mitochondrial function and the circadian clock.86 
Therefore, TRF appears to function in the mammalian liver 
and microbiome, as well as the fruit fly heart to improve pa-
thologies related to aging and metabolic function.
The number of ways that metabolism, sleep, and circadian 
pathways are integrated continues to expand. An emerging 
body of evidence indicates intimate links between epigenetic 
modifications and broad metabolic changes in the animal. Met-
abolic status, including levels of NAD (nicotinamide adenine 
dinucleotide), SAM (s-adenosyl methionine), FAD (Flavin ad-
enine dinucleotide), acetyl CoA, and potentially glucose levels, 
all result in differential histone modifications. These modifi-
cations impact the transcription of the nearby genes through 
DNA accessibility and thus serve as a potential gene regulatory 
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system for key metabolic enzymes. Therefore, this system may 
connect diet to the transcript oscillations of metabolic genes.79 
To understand this connection, Dr. Paolo Sassone-Corsi and 
colleagues have coupled a metabolic approach to quantify cy-
cling metabolites under high fat and normal food conditions 
with an analysis of chromatin modulating enzymes. Previous 
work has shown that ~50% of metabolites oscillate in the liver, 
suggesting they may be functionally downstream of the circa-
dian clock.87 These data are openly shared on the web resource 
CircadiOmics, presenting a rich resource for the community. 
Feeding mice a high fat diet over 10 weeks both disrupts the 
cycling of one set of genes and metabolites in the liver but also 
induces the cycling of a second class of genes and metabolites 
that do not cycle under normal diet conditions.88 These data 
further suggest that levels of NAD+ may play a role in this 
switch. NAD+ is a cofactor for SIRT1 to activate CLOCK/
BMAL1 transcriptional activity. To further understand the 
connection between diet, metabolic enzymes and circadian 
cycling, the Irvine group compared knockouts of two proteins 
thought to modify the chromatin environment.89 SIRT1 and 
SIRT6 are chromatin deacetylases expressed in similar cells. 
Comparing gene expression and metabolic profiles suggests 
that they have different targets with only about 10% overlap in 
gene expression between the 2 knockout mice. Moreover, met-
abolic constituents such as lipids and carbohydrates are mark-
edly different between the 2 knockout mice. Therefore, one 
role of the circadian clock could be to regulate specific deacet-
ylases which then partition metabolic output of the liver. For 
example, SIRT1 controls chromatin changes that permit tran-
scription of peptide and cofactor genes while the presence of 
SIRT6 permits transcription of lipid and carbohydrate related 
genes. Thus, chromatin modifications likely play a critical role 
in the rhythmicity and function of the circadian system.
Taken together, these studies further our understanding of 
the reciprocal interaction between conserved metabolic and 
circadian pathways. Metabolic input modulates clock depen-
dent gene expression, while alterations in circadian clocks can 
alter critical metabolic functions that impact diverse physiolog-
ical processes related to health and pathology. Understanding 
how diet and cellular metabolism regulate circadian function 
will require a better understanding of the mechanisms linking 
these processes. Model organisms will play a major role in 
investigating the molecular connections between conserved 
metabolic and timing pathways. From fruit flies to mice, these 
organisms permit genetic and biochemical approaches that 
expand our understanding of the molecular connections that 
will likely translate to an improved understanding of human 
health and potential treatments. The studies presented pro-
vide a strong rationale for the future use of genetically ame-
nable model systems to provide a framework that will guide 
clinical studies.
SESSION IV: APPROACHES TO UNDERSTANDING THE 
MECHANISMS CONTRIBUTING TO GLUCOSE HOMEOSTASIS
Effective treatment of metabolic diseases, such as type 2 
diabetes, requires circulating blood glucose to be maintained 
within a relatively narrow range. Both hyperglycemia and hy-
poglycemia are associated with specific risks posing a signifi-
cant challenge for treatment of individuals with diabetes. In 
the fourth session, speakers focused on various approaches 
used to understand the physiological mechanisms contributing 
to regulation of glucose homeostasis.
Dr. Sam Klein opened the session with a dataset highlighting 
the importance of looking beyond body mass index (BMI) as 
an indicator of metabolic health. Patients with similar BMIs, 
exhibit a wide range of insulin sensitivity as measured by 
using the hyperinsulinemic-euglycemic clamp procedure, in-
dicating that BMI-independent physiological parameters con-
tribute to differences in insulin sensitivity. Instead of BMI, Dr. 
Klein characterizes obese patients based on metabolic status, 
and in particular on the ability of insulin to stimulate glu-
cose uptake and intrahepatic triglyceride content. People with 
normal levels of intrahepatic triglyceride are usually “meta-
bolically normal” and those with high levels of intrahepatic 
triglyceride are usually “metabolically abnormal.” 90 In fact, 
the amount of intrahepatic triglyceride is directly associated 
with the degree of insulin resistance, and has been used as a 
marker of metabolic dysfunction. Klein’s findings demonstrate 
that metabolically abnormal obese subjects are more likely to 
exhibit adverse metabolic profiles including high blood pres-
sure, plasma triglycerides, and very low-density lipoprotein 
(VLDL), and decreases in multi-organ insulin sensitivity in 
response to moderate (6%) weight gain compared to similar 
weight gain in metabolically normal obese subjects.90 Impor-
tantly, these data indicate that investigators must take into 
account the metabolic status of a patient, not just their body 
weight when investigating changes in metabolic health. A sys-
tems biology research approach in human subjects is needed 
to provide a comprehensive assessment of the effect of sleep 
and circadian disruption on metabolic function. These studies 
involve sophisticated metabolic testing, such as the hyperin-
sulinemic-euglycemic clamp procedure, in conjunction with 
isotope tracer infusion and tissue biopsies, to dissect the com-
plex and interactive effects of sleep and circadian disruption 
on multiple organ systems simultaneously.91 The various com-
ponents that need to be addressed to provide a comprehensive 
assessment are outlined in Figure 1.
Dr. Philip Kern spoke about adipose tissue inflammation 
and its role in insulin resistance. In a normal, healthy state, 
adipose tissue expands to meet lipid storage demands. Dys-
functional adipose expansion results in an increase in the 
secretion of inflammatory cytokines, such as tumor necrosis 
factor-α (TNF-α) and IL-6. Indeed, elevated TNF and IL-6 
expression in human adipose tissue is associated with insulin 
resistance independent of obesity. Furthermore, unhealthy 
adipose tissue in insulin resistant subjects is typically charac-
terized by increased levels of inflammatory macrophages, in-
creased extracellular matrix materials and increased numbers 
of mast cells.92 Treatment with pioglitazone, a peroxisome pro-
liferator-activated receptor gamma (PPARγ) agonist, improves 
insulin resistance, decreases inflammation, and changes adi-
pose tissue physiology—leading to smaller adipose cells with 
paradoxically larger total adipose tissue mass fat storage po-
tential.92 Facilitating adipose tissue expansion via healthier ad-
ipocytes may directly benefit glucose metabolism by reducing 
plasma FFA and adipokine secretion.93 In addition to adipose 
cell size, the processes of white adipose tissue changing to 
a more metabolically-active brown/beige fat, is also a key 
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physiological component and may contribute to 
overall metabolic health.94,95 Again, investigators 
must examine the specific role of key metabolic 
tissues, such as adipose tissue, in determining a 
patient’s metabolic health and not rely solely on 
BMI status.
Dr. Elizabeth Seaquist focused on peripheral 
and central nervous system responses to hypo-
glycemia and revealed some intriguing interac-
tions with sleep. Hypoglycemia, which often 
occurs during insulin therapy for patients with 
either type 1 or type 2 diabetes, is the major lim-
iting factor in reaching optimal glycemic target 
goals. Dr. Seaquist first reviewed the physiology 
that underlies the counter-regulatory responses 
to hypoglycemia and discussed that repeated 
episodes of hypoglycemia decrease the auto-
nomic and adrenal medullary response to elicit 
an efficient, timely counter regulation to falling 
glucose levels. If this autonomic failure occurs 
during sleep, the plummeting glucose levels can 
lead to death. During recurrent hypoglycemia, 
the brain appears to use glycogen as an alter-
native fuel source and, as a result, has altered 
glucose sensing. She showed evidence that the 
thalamus of patients with type 1 diabetes dis-
played an impaired awareness of hypoglycemia 
and the thalamus did not show the pattern of 
neuronal activation during hypoglycemia as 
seen in healthy volunteers.96 Moreover, Seaquist 
discussed that hypoglycemia during sleep can 
affect other parameters, such as morning food 
intake and memory consolidation. Dr. Seaquist 
highlighted the importance of studying the brain 
in humans when investigating the effects of sleep 
on metabolism and novel imaging strategies can 
advance this area of science.
As discussed in the first session, sleep apnea is associated 
with dysregulated glucose metabolism. Dr. Michael Joyner 
continued the OSA discussion with a focus on the carotid 
bodies (CB). During a hypoxic event, the CBs sense the drop 
in oxygen saturation and activate the sympathetic nervous 
system (SNS) which in turn may contribute to increased en-
dogenous glucose production as observed in patients with OSA 
who repeatedly suffer cyclical intermittent hypoxia. In support 
of this, Dr. Joyner presented findings demonstrating decreased 
counter-regulatory hormone responses and increased glucose 
infusion rates during a hypoglycemic clamp in humans under 
hyperoxic conditions that “turn off” CBs relative to normoxic 
conditions.97 Moreover, CBs sense more than just hypoxia and 
also respond to glucose, insulin, and pro-inflammatory cy-
tokines.98–100 Narkiewicz et al.101 reported that obese patients 
without OSA have similar SNS activity relative to normal pa-
tients whereas obese patients with occult OSA have elevated 
SNS activity relative to normal patients and obese patients 
without OSA. These findings indicate OSA may be obligatory 
for elevated SNS activity in obese patients. In conclusion, Dr. 
Joyner’s data suggest that CBs are involved in dysregulated 
glucose metabolism in OSA patients, highlighting that CBs 
sense more than just hypoxia and also respond to glucose, in-
sulin, and pro-inflammatory cytokines.
Dr. Richa Saxena concluded session IV with a discussion 
about the role of genetics and potential interactions with sleep, 
circadian timing, and type 2 diabetes (T2D) risk. Common 
variants in the melatonin receptor gene, MTNR1B, are associ-
ated with increased type 2 diabetes risk.14,15 Specifically, indi-
viduals with the G allele have a reduced insulin response to 
glucose and reduced disposition index (a validated T2D risk 
marker). To further investigate these associations, Dr. Saxena 
in collaboration with Dr. Frank Scheer at Harvard’s Division of 
Sleep Medicine has assessed MTNR1B variation in individuals 
with specific measures of sleep and circadian physiology from 
over 20 laboratory controlled studies. Preliminary findings 
suggest that individuals with the GG allele have later timing 
of their dim-light melatonin offset and a longer duration of el-
evated melatonin. Furthermore, carriers of this T2D MTNR1B 
risk allele have decreased glucose tolerance during an oral glu-
cose tolerance test relative to non-carriers under conditions of 
exogenous melatonin administration. Based on these findings, 
Dr. Saxena proposed a model where individuals with the T2D 
MTNR1B risk allele have elevated melatonin levels later in the 
Figure 1—Pathogenesis of obesity-related metabolic dysfunction. Studies of metabolic 
dysfunction in people need to provide a comprehensive approach and consider the 
complex changes that occur in multiple organs. Specifically, the following need to be 
assessed: (1) changes in adipose tissue biology that can be assessed by fat biopsies; 
(2) adipose tissue lipolytic activity and the release of free fatty acids (FFA) into the 
bloodstream; (3) adipokines; (4) metabolic changes in the liver, including intrahepatic 
triglyceride content; (5) very low density lipoprotein (VLDL) secretion rate; (6) de novo 
lipogenesis rates, fatty acid oxidation and liver insulin sensitivity; (7) changes in muscle 
insulin sensitivity and metabolite content, (8) β-cell function; (9) gut microbome; and (10) 
the brain plays an important role in glucose and lipid homeostasis, receiving information 
from periphery signals generated by food ingestion and subsequently contributing to 
the regulation of metabolism through innervation of metabolically active tissues such as 
muscle, pancreas, liver and adipose tissue. In obesity-related pathogenesis, increased 
sympathetic activation increases lipolysis and stimulates hepatic glucose production. 
Figure provided by Dr. Sam Klein.
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morning when they are normally consuming food and this in-
teraction of elevated melatonin with concurrent food intake 
mediates dysregulated glucose metabolism and increased T2D 
risk. Importantly, findings from studies that use melatonin as 
a marker of circadian phase show that circadian misalignment 
results in dysregulated glucose metabolism.19,20 These previous 
studies do not assess a causal role of melatonin in mediating 
dysregulated glucose metabolism but show that circadian mis-
alignment in general results in dysregulated glucose metabo-
lism. Dr. Saxena proposes that melatonin may have a direct role 
in mediating dysregulated glucose metabolism in individuals 
with the T2D MTNR1B risk allele. Together with the previous 
speakers, these findings provide further evidence that we need 
to take a multi-faceted approach to investigating the impact of 
sleep and circadian disruption on dysregulated glucose metab-
olism and T2D risk, including the role of genetic variants that 
underlie individual differences in response to sleep disorders 
and circadian disruption.
SESSION V: CURRENT/ONGOING STUDIES ON SLEEP AND 
CIRCADIAN DISRUPTIONS IN HUMANS
Dr. Frank Scheer addressed the separate effects of the cir-
cadian system, the behavioral cycle and their interaction, i.e., 
circadian misalignment, on human metabolism. In a forced 
desynchrony protocol, circadian misalignment rapidly (after 
just 3 days) increased the postprandial responses of glucose 
and insulin, demonstrating reduced glucose tolerance and sug-
gesting reduced insulin sensitivity.19 In the same study, circa-
dian misalignment decreased levels of the satiety hormone 
leptin. These effects, if maintained chronically, could help 
explain why shift work is a risk factor for diabetes and obe-
sity, respectively. In this study, these effects could not be fully 
explained by changes in sleep duration. This conclusion was 
supported by an elegant experimental study in which circadian 
misalignment reduced insulin sensitivity without changes in 
sleep duration.20 In a recent simulated night work study, the 
independent effects of circadian phase and circadian misalign-
ment on glucose tolerance were investigated.102 Postprandial 
glucose levels were higher in the biological evening than in 
the biological morning independent of behavioral cycle effects 
(including sleep/wake and fasting/feeding cycle), and this cir-
cadian influence was much larger than the effect of the behav-
ioral cycle, indicating a dominant role of the circadian system 
in the well-known daily rhythm in glucose tolerance. In addi-
tion, circadian misalignment resulting from a rapid 12-h shift 
of the behavioral cycle decreased glucose tolerance. This effect 
was sustained over 3 days of night work exposure, providing 
additional evidence for circadian misalignment as a mecha-
nistic link between shift work and increased diabetes risk. In-
terestingly, these variations in glucose tolerance seemed to be 
explained, at least in part, by different mechanisms: decreased 
pancreatic β-cell function (lower early-phase insulin) during 
the biological evening and decreased insulin sensitivity (el-
evated postprandial glucose despite higher late-phase insulin) 
without change in early-phase insulin during circadian mis-
alignment. Even the timing of meals and the distribution of 
caloric intake during the daytime has recently been found to 
influence energy balance in humans. In a large longitudinal 
weight loss study, overweight and obese individuals who ate 
their main meal early lost about 25% more weight than those 
who ate their main meal late, despite similar caloric intake and 
physical activity.103 In a subsequent experimental study, this 
general concept was confirmed, showing that a high-caloric 
breakfast rather than a high-caloric dinner during a weight loss 
diet resulted in improved weight-loss despite similar 24-hour 
caloric intake.104 Not only does the circadian system influence 
the physiological and metabolic response to meals, the circa-
dian rhythm has also been shown to influence subjective hunger 
and appetite independent of the fasting/feeding cycle, with a 
peak in the biological evening and a trough in the biological 
morning.105 Finally, one of the factors that may be involved in 
the adverse effects of circadian misalignment on glucose toler-
ance is the elevated melatonin concentration during nighttime 
food intake. Dr. Scheer presented a study that showed that a 
pharmacological dose of melatonin decreased glucose toler-
ance assessed by an oral glucose tolerance test, regardless of 
whether melatonin was administered in the morning or eve-
ning.106 These results suggest caution when using melatonin 
close to meals.
Dr. Kenneth Wright addressed the impact of insufficient 
sleep and circadian misalignment on metabolism in humans. 
The effect of insufficient sleep on total daily energy expendi-
ture (whole room calorimetry) and energy balance was exam-
ined in a 2-week long protocol.107 Subjects were allowed ad 
libitum food intake and were scheduled to 5 h (insufficient) 
and 9 h sleep opportunities. Findings demonstrated that al-
though energy expenditure increased during the insufficient 
sleep condition, subjects also increased nutrient consumption, 
particularly carbohydrates eaten as post-dinner snacks. This 
resulted in a net positive energy balance and weight gain. In-
sufficient sleep led to a delay in the timing of melatonin onset 
and an increased duration between wake time and circadian 
melatonin offset phase, which likely contributed to changes 
in eating behaviors. Dr. Wright reviewed previous work dem-
onstrating that eating during the typical sleep period contrib-
utes to weight gain in mice,108 and he suggested that eating 
at inappropriate circadian times may be a novel risk factor 
for weight gain and obesity. The effect of circadian misalign-
ment on energy expenditure was examined in a 6 day protocol 
simulating a common night shift work schedule.109 Total daily 
energy expenditure decreased during the shift work schedule 
following the transition day to the night shift. Such a decrease 
in total daily energy expenditure implies that even if food in-
take is maintained, a nightshift schedule could lead to weight 
gain; this effect would be exacerbated if physical activity was 
decreased and food intake increased under such conditions. 
Dr. Wright noted that findings from epidemiological studies 
suggest that there are long-term metabolic effects of night 
shift work, but controlled laboratory studies to assess these 
effects are necessarily limited in duration. This observation 
highlighted a recurrent discussion topic at the workshop re-
lating to the need to design studies that could address precise 
physiological questions in the context of real-world situations. 
For example, how is energy expenditure altered in people 
who have been working a night shift for an extended period 
of time?
Dr. Charles Czeisler reviewed the effects of light exposure 
on sleep and circadian rhythms and discussed some of the 
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implications for metabolism and metabolic diseases. To pro-
vide historical context, he cited studies demonstrating that av-
erage sleep durations have declined over the past 100 years.110 
Both the phase of the clock and melatonin secretion, a marker 
of circadian phase, are known to be highly sensitive to light: 
even dim room light can affect plasma melatonin concen-
trations and the phase of the intrinsic pacemaker.111 Current 
practices, such as reading light-emitting eReaders instead of 
books, introduce additional phase-delays and acutely suppress 
melatonin secretion.112 Epidemiological studies have linked 
the short sleep durations and circadian disruption prevalent 
in modern society to a range of negative health outcomes in-
cluding a higher risk of metabolic syndrome and diabetes. Dr. 
Czeisler presented his work showing that in humans 3 weeks 
of sleep restriction (5.6 h of sleep opportunity per 24 h) concur-
rent with circadian disruption increases postprandial glucose 
levels, possibly due to impaired β-cell function.113 These ad-
verse alterations were abolished following 9 days of recovery 
sleep and circadian re-entrainment to a normal sleep/wake 
cycle. These results suggest that inter-individual differences 
in circadian phase may translate to differential metabolic risks. 
When intrinsic circadian periods were assessed in healthy 
adults, over 75% of subjects had periods longer than 24 h.114 
However, intrinsic circadian periods tended to be shorter in 
women, consistent with results from studies in nonhuman ani-
mals.115,116 More work is needed to determine the relationships 
between intrinsic circadian period and susceptibility to circa-
dian disruption and resulting metabolic effects.
Dr. Louis Ptacek discussed his research on heritable human 
circadian and sleep variants. Dr. Ptacek described a 3-process 
conceptual model that includes the clock, the homeostat, and 
behavioral drive. He cited several studies in which mutations 
in clock genes were linked to familial sleep-wake phenotypes 
including advanced and delayed sleep phase and natural short 
sleep.117–120 He provided several examples of cases in which 
genetic traits of the clock and sleep homeostat inform other 
phenotypes. For example, mutations in casein kinase 1δ cause 
familial advanced sleep phase and migraine with aura.121 An-
other family with a circadian gene mutation also has depres-
sion with a seasonal component. Interestingly, mice carrying 
this mutation also have measures of “depression-like behavior” 
that are sensitive to light cycles. He also reviewed animal 
studies in which these phenotypes were explored explicitly. 
For example, modulation of O-GlcNAcylation was identified 
in a chemical genetic screen of GSK3β (glycerol synthase ki-
nase). O-GlucNAc transferase (OGT) and O-GlucNAse (OGA) 
were identified as GSK3β targets and novel circadian genes. 
Alterations of circadian period in cells, mice and Drosophila, 
resulted from manipulations of OGT and OGA. Reciprocal 
regulation of circadian clock and protein O-GlcNAcylation is 
therefore a direct connection between clock and metabolism.122 
Dr. Ptacek also discussed results suggesting that these interac-
tions are also impacted by glucose levels. Given the plethora 
of data linking chronic desynchrony and sleep deprivation 
with increased risks of many health consequences, including 
metabolic disorders, further exploration of subjects from ad-
vanced sleep phase and natural short sleep families is impor-
tant to see whether these genetic forms also confer risk (or 
protection) to metabolic effects. In addition, mouse models of 
many of the identified human mutations are available for such 
investigations.
CONCLUSIONS
Several important themes emerged from this workshop. 
First, it is essential that we encourage joint principal inves-
tigators with investigators from the sleep/circadian research 
community on the one hand and investigators in metabolism, 
glucose control, etc. on the other. There is much to be gained 
from fostering interaction.
Sleep/circadian investigators in human studies need to move 
beyond studies of insulin and glucose and conduct studies at a 
molecular level assessing effects on key end organs such as fat 
and muscle that can be assessed in investigations in humans. 
The microbiome needs to be considered. Investigators in metab-
olism need, in turn, to consider the role of inadequate sleep, cir-
cadian mal-alignment and sleep disorders such as sleep apnea 
in their human studies. It is conceivable that they play a role 
in differentiating the metabolically impaired compared to not 
impaired obese subjects. The techniques to assess sleep, sleep-
disordered breathing have markedly improved and assessments 
do not require in-laboratory studies thereby reducing protocol 
burden. New mobile approaches are developing and assessment 
of sleep, sleep-disordered breathing should be part of all on-
going cohort studies and clinical trials in diabetes, etc.
Another important theme was the concern that while acute 
studies in simulated inadequate sleep, as well as shift work, 
using in-laboratory studies in healthy volunteers had the ad-
vantage of control of many key variables, the results may 
not extrapolate to real-world chronic “cases” in the commu-
nity since chronic adaptations may occur. There is a need for 
complementary studies in individuals with chronic inadequate 
sleep and shift workers using in-depth metabolic phenotyping.
Attention also needs to expand beyond the traditional meta-
bolic systems—liver, pancreas, adipose tissue and muscle—but 
also include the carotid body and brain. Novel neuroimaging 
approaches in humans with inadequate sleep/shift work is an 
area of opportunity.
Studies also need to incorporate evaluation of genetic and 
epigenetic changes. There is a rapidly developing under-
standing of both rare and common variants and it is important 
to understand whether variants that affect sleep also affect me-
tabolism and vice versa.
A number of specific areas for immediate translational re-
search were identified. Current findings suggest that there is a 
need for the following: a) clinical trials to assess impact of OSA 
on metabolic health. A particular area of opportunity is likely 
to be in pre-diabetes, i.e., before β-cell failure has occurred. 
Given the very high prevalence of obstructive sleep apnea in 
obese individuals, identification and treatment of OSA could 
be a preventative strategy to reduce development of diabetes; 
b) more in-depth studies are also needed to investigate whether 
food timing can be used as a novel preventative or therapeutic 
strategy in patients with or at risk for type 2 diabetes,123 par-
ticularly in shift workers, in obese and overweight individuals.
We also need to explore the underlying neuroendocrine, cel-
lular and molecular mechanisms that influence energy expendi-
ture, physical activity, hunger and appetite control, and eating 
behaviors. A particular area of opportunity is to establish the 
SLEEP, Vol. 38, No. 12, 2015 1858 Sleep/Circadian Disruption in Diabetes—Arble et al.
interaction of food intake with melatonin profiles including un-
derstanding the role of genetic variations in circadian-related 
genes associated with diabetes risk, e.g., MTNR1B and CRY2.
Thus, this is an area with many opportunities for transla-
tional research and it is to be hoped that this workshop catalyzes 
the development of this important area of inquiry.
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